

Article

Development and validation of a rapid lateral flow E1/E2-antigen test and ELISA in patients infected with emerging Asian strain of Chikungunya virus in the Americas

Ankita Reddy,^{†1,2} Irene Bosch,^{†*1,2,3} Nol Salcedo,¹ Bobby Brooke Herrera,^{1,4} Helena de Puig,^{2,5} Carlos F. Narváez,⁶ Diana María Caicedo-Borrero,⁷ Ivette Lorenzana,⁸ Leda Parham,⁸ Kimberly García,⁸ Marcela Mercado,⁹ Angélica María Rico Turca,¹⁰ Luis A. Villar-Centeno,¹¹ Margarita Gélvez-Ramírez,¹¹ Natalia Andrea Gómez Ríos,¹¹ Megan Hiley,² Dawlyn García,² Michael S. Diamond,¹² Lee Gehrke^{1,2,13}

¹ E25Bio, Cambridge, MA, 02139, USA

² Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, 02139, United States of America

³ Department of Medicine, Mount Sinai School of Medicine, New York, NY, 10029, USA

⁴ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA

⁵ Wyss Institute for Biologically Inspired Engineering, Harvard Medical School, Boston, MA, 02115, United States of America

⁶ Programa de Medicina, Facultad de Salud, Universidad Surcolombiana, Neiva, Huila, Colombia

⁷ Departamento de Salud Pública y Epidemiología de la Pontificia Universidad Javeriana Cali y Escuela de Salud Pública de la Universidad del Valle, Cali, Colombia

⁸ Instituto de Investigación en Microbiología, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras

⁹ Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia

¹⁰ Laboratorio de Virología, Dirección de Redes en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia

¹¹ Universidad Industrial de Santander and AEDES Network, Bucaramanga, Santander, Colombia,

¹² Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, Saint Louis, MO, 63110, USA

¹³ Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, 02115, USA.

† These authors contributed equally to this work.

* Correspondence: ibosch@e25bio.com

Abstract: Since its 2013 emergence in the Americas, chikungunya virus (CHIKV) has posed a serious threat to public health. Early and accurate diagnosis of the disease, though currently lacking in clinics, is integral to enable timely care and epidemiological response. We developed a dual detection system: a CHIKV antigen E1/E2-based enzyme-linked immunosorbent assay (ELISA) and a lateral flow test using high-affinity anti-CHIKV antibodies. The ELISA was validated with 100 PCR-tested acute Chikungunya fever samples from Honduras. The assay had an overall sensitivity and specificity of 51% and 96.67%, respectively, with accuracy reaching 95.45% sensitivity and 92.03% specificity at a Ct cutoff of 22. As the Ct value increased from 22, ELISA sensitivity decreased. We then developed and validated two lateral flow tests using independent antibody pairs. The sensitivity and specificity reached 100% for both lateral flow tests using 39 samples from Colombia and Honduras at Ct cutoffs of 20 and 27, respectively. For both lateral flow tests, sensitivity decreased as the Ct increased after 27. Because CHIKV E1/E2 are exposed in the virion surfaces in

serum during the acute infection phase, these sensitive and specific assays demonstrate opportunities for early detection of this emerging human pathogen.

Keywords: Chikungunya fever; ELISA; lateral flow; E1/E2 antigen detection; alphavirus; Latin America; acute phase diagnosis; rapid diagnosis

1. Introduction

Chikungunya virus (CHIKV) is an increasingly prevalent alphavirus that is transmitted by *Aedes* mosquitoes [1]. In recent years, CHIKV has re-emerged at an unprecedented rate, spreading to over 100 countries across five continents and producing over one million infections annually [2–4]. As mosquito breeding grounds expand in response to climate change and globalization, CHIKV infections are expected to pose an even greater threat to public health.

Chikungunya fever, which is caused by infection of CHIKV, is a debilitating disease which often includes joint pain and high fever, and a plethora of additional nonspecific symptoms including rash, abdominal pain, vomiting, diarrhea, myalgia, and headache. Although the acute clinical manifestations often subside after 1-3 weeks, chronic joint pain lasting months to years can significantly impair movement and undermine quality of life [5]. Severe forms of Chikungunya fever also include neurological complications, myocarditis, pneumonia, lymphadenopathy, hepatitis, and pancreatitis [2]. Treatment for chikungunya fever is mainly supportive and symptomatic, but early diagnosis is vital to enabling care and preventing further complications that can be debilitating and life-threatening. Early diagnosis also allows patient triaging and infection surveillance for timely care and disease prevention, particularly during outbreaks.

CHIKV is difficult to diagnose solely through clinical findings due to the nonspecific nature of the febrile diseases symptoms [6,7]. The nonspecific symptoms overlap with dengue (DENV) and Zika (ZIKV) viruses - diseases that often co-circulate with CHIKV - rendering accurate diagnosis particularly complex during the first days of disease [6,8–10]. Because disease outcomes and supportive treatment significantly differ between these three diseases, accurate diagnosis is critical to outbreak control, surveillance, and prevention [11]. Accurate diagnosis is also significant for research related to vaccine efficacy and drug development.

CHIKV contains an 11.8 kb positive-sense, single-stranded RNA genome. The virus encodes four conserved non-structural proteins (nsP 1-4), a capsid protein, two envelope glycoproteins (E1 and E2), and two cleavage products (E3 and 6K) [12]. The E1 and E2 proteins offer an ideal target for diagnosis because they are secreted at high concentrations into human blood during the acute phase of infection when viremia is high.

Presently, there is an urgent need for an accurate and early diagnosis during the acute phase for CHIKV-infected patients to enable rapid clinical response and appropriate epidemiological surveillance. Currently available methods of diagnosis include viral isolation, polymerase chain reaction (PCR) [13–18], and serological tests such as IgM/IgG lateral flows, enzyme-linked immunosorbent assay (ELISAs), and indirect immunofluorescent assays (IIFAs) [19–22]. All of these assays contain significant barriers to enabling appropriate outbreak response, ranging from high costs and lengthy testing times to post-acute phase diagnosis.

In this study we describe the development and performance of two methods of diagnosis that enable early and accessible diagnosis: an E1/E2 antigen-based test in both an ELISA and rapid lateral flow format. Our data indicates high specificity and sensitivity of the tests using infected samples from the CHIKV endemic regions of Honduras and Colombia, areas severely underrepresented in previous studies.

2. Materials and Methods

Study Design

This study aimed to develop a CHIKV antigen-based ELISA and lateral flow tests and to validate their accuracy of the assays using PCR-confirmed acute fever serum samples. All tests were performed on-site at the University of Tegucigalpa in Honduras and the Instituto Nacional de Salud in Colombia. All limit of detection experiments were conducted in a biosafety level (BSL) 3 laboratory at the Ragon Institute.

Clinical Samples

A total of 129 acute chikungunya fever clinical serum samples and 60 negative patient samples were used in this study. Of these samples, 100 fever samples and 60 negative samples were collected by medical personnel from Honduras at the University of Tegucigalpa in Honduras. The remaining 29 acute fever samples were collected by medical personnel at the Instituto Nacional de Salud in Colombia. All clinical serum samples were de-identified and collected during the acute phase (1 to 5 days after the onset of illness). All patients from each of the cohorts provided informed consent for the original collection of the samples. The primary studies under which the samples and data were collected received an exemption determination from the Massachusetts Institute of Technology Internal Review Board (IRB) and local research ethics committees at University of Tegucigalpa, Honduras (Comite Etico en Investigación Biomedica, ID: NMRC2010.0010) and Instituto Nacional de Salud in Colombia (INS Ethics Committee, ID: CTIN-31-2015).

Antibody Production and Selection

CHIKV antibodies for Combination A (48 and 155) were generated previously in mice [23]. A total of 1056 antibodies were harvested from the hybridomas. To maximize sensitivity and sensitivity, antibodies were produced and selected through mouse immunization and a set of two screening methods. The binding of these antibodies to CHIKV VLP were measured by ELISA. Response was measured as fold above background, by subtracting the negative control OD₄₅₀ from the OD₄₅₀ of interest, and then dividing by the negative control OD₄₅₀. The binding of antibodies to the genetically related Mayaro virus (MAYV) VLP was measured for counter-screening. The 48 antibodies with the highest fold above background to CHIKV VLP but with low binding affinity to MAYV VLP using the primary ELISA screen underwent a secondary screen by fluorescent-activated cell sorting (FACS) designed to evaluate the recognition of monoclonal antibodies to CHIKV-infected Vero cells. The antibodies that stained positively by flow cytometry on infected cells were isotyped and purified using Protein L or Protein G according to their light chain binding epitopes. The antibody pairs were evaluated on a dipstick format and selected based upon the lowest limit of detection and dissociation constant through image analysis, as adapted from Bosch et al [24].

ELISA for the detection and quantification of CHIKV E1/E2

To validate the E1/E2 ELISA, 100 fever samples and 60 negative samples from Honduras were tested using an adapted protocol from Bosch et al [24]. Detection antibodies were first biotinylated using ThermoFisher Scientific EZ-Link Sulfo-NHS-LC-Biotinylation Kit, according to the manufacturer's instructions (cat no. 21335, Pierce Biotechnology). To prepare the ELISA, ninety-six-well CoStar flat bottom high binding plates (cat. no 3590, Corning) were coated with 100 µl of the specific antibody (mAb 155) at a 1 µg/ml, diluted in 1X PBS pH 7.4 (cat no. 10010031, Gibco). After incubating the plates overnight at room temperature, the antibody was discarded and each well was incubated for 2 hours at room temperature with 200 µl/well of 5% Blotto (cat. no. sc-2325, Santa Cruz Biotechnology) made from 5% nonfat dry milk (cat. No. sc-2325, Santa Cruz Biotechnology) and 0.05% Tween 20 (cat. no. p-1379, Sigma-Aldrich) diluted in PBS. After discarding the liquid, 50 µl of serum sample diluted in 50 µl 2.5% Blotto in PBS were incubated in each well for 1 hour at room temperature. After washing the plates three times with 0.1% Tween 20 in PBS, 100 µl/well of biotin-labeled mAb 48 at 1 µg/ml was incubated for 1 hour at room temperature. The plates were washed four times with the 0.1% Tween 20 solution. One hundred µl/well of peroxidase-labeled streptavidin High Sensitivity (cat. no 21130, Thermo-Fisher Scientific) at 1:1000 dilution, diluted in 2.5% Botto,

was added and incubated for 1 hour at room temperature. The plates were again washed four times with the 0.1% Tween 20 in PBS. Following the wash steps, 100 μ l/well of tetramethylbenzidine single solution (cat. no 002023, Life Technologies) were pipetted into each well to develop the color reaction and stopped by the addition of 50 μ l/well of 2M Sulfuric acid (cat. no. 8315-32, Ricca Chemical Company). The plates were read by a TriStar LB 941 spectrophotometer (Berthold Technologies) at a wavelength of 450 nm.

Lateral Immune Detection Methods for the quantification of CHIKV E1/E2

The E1/E2 lateral flow test was validated using 29 fever serum samples, of which 19 samples were from Honduras and 10 were from Colombia. Dipstick and lateral flow assays were constructed in the lab using an adapted protocol. Briefly, forty-nanometer gold nanoparticles (Innova Biosciences) were conjugated to the CHIKV antibodies according to the manufacturer's instructions. The antibody was first diluted to 0.1 mg/ml in the supplied dilution buffer. Next, 12 μ L of diluted antibody were mixed with 42 μ L of reaction buffer. Forty-five microliters of the mix were then used to suspend the lyophilized gold nanoparticles (OD₂₀). The antibody-nanoparticle mix was incubated for 10 min at room temperature, followed by the addition of 5 ml of quencher solution to stop the coupling reaction. After adding the quencher solution, 100 ml of 1% Tween 20 in PBS and 50 ml of 50% sucrose in water were added to the conjugates before use in immunochromatography. Dipsticks were used to screen antibodies and collect limit of detection values. Lateral flows were used to collect limit of detection values and test patient samples in the field.

Image Analysis

Lateral flow tests were analyzed through image analysis to quantify the signal intensity on the strip. Following test runs, the strips were machine scanned and converted to greyscale. ImageJ software was used to quantify the signal in the test area and in the positive control area. The normalized signal was computed as a ratio of the test to positive control, and this data was used in LoD calculations and ROC analyses.

Limit of Detection (LoD) Analysis

R software was used to calculate the limits of detection (LoD) and dissociation constant (K_d) for each antibody pair in each diagnostic format. The K_d was derived by keeping each antibody concentration constant and running decreasing concentrations of either CHIKV E1 and E2 protein or CHIKV virus-like particles (VLP). The results were fitted using a Langmuir equation, $gray_n = [antigen]/K_d + [antigen]$, where $gray_n$ is the normalized signal intensity on the lateral flow, $[antigen]$ is the concentration of E1/E2 or VLP and K_d is the effective binding constant in a Langmuir-like system. The LoD was measured as the concentration of E1/E2 or VLP that displayed a signal 5 times the value of the standard deviation of the negative control.

RNA Extraction and Quantitative RT-PCR

Samples were collected and processed for RNA extraction followed by RT-PCR in each of the participating laboratories. RNA was extracted according to the QIAamp Viral RNA Mini Handbook for purification of viral RNA from plasma, serum, cell-free body fluids and culture supernatants (cat no. 52904, Qiagen). Virus identity including serotypes was determined using quantitative PCR. The Fast Track Diagnostics Dengue/Chik real-time PCR protocol and reagents were used to process samples in India, according to the manufacturer's instructions (TaqMan). The Agpath-ID One-Step Real-Time PCR protocol and reagents were used to process samples in Honduras and the CDC Triplex Real-Time PCR protocol and reagents were used to process samples in Colombia, according to the manufacturers' instructions.

Receiver Operator Characteristic (ROC) Analysis

GraphPad Prism 8.0 software was used to report the performance of the ELISA, Receiver Operating Characteristic (ROC) curves. The ROC curve presents test performance as True Positive Rate (% sensitivity) versus False Positive Rate (100% - % specificity). Optimal cutoff values, which maximize sensitivity and specificity, were calculated from the ROC curve also using GraphPad Prism 8.0. The sensitivity is defined as the fraction of total confirmed positive samples that are true positives according to the test. The specificity is defined as the fraction of total confirmed negative samples that are true negatives according to the test. Confidence intervals (CI) using the Wilson/Brown method and Area Under Curve (AUC) were calculated for each serotype and PAN using GraphPad.

3. Results

3.1. Antibody Selection for CHIKV ELISA and Lateral Flow Assays

Of 1056 antibodies harvested from the CHIKV-immunized mice, mAb 48 with mAb 155 (Combination A) and mAb B.1 with mAb B.2 (Combination B) were selected for the sandwich ELISA and lateral flow tests. The ELISA screening of the 48 chosen antibodies displayed low or non-existent detection for MAYV VLP across all antibody clones, with 73% of the clones presenting at least 20 fold above background (Figure S1). The two antibody pairs, Combination A and B, were chosen based upon the high CHIKV VLP binding affinity and discrimination between CHIKV VLP and MAYV VLP determined from the ELISA and flow cytometry of infected cell screening as well as the low limits of detection. Combinatorial dipstick analysis was also performed to select the antibody combinations, demonstrating high binding affinity in a rapid test format (data not shown).

3.2. Limits of Detection

The limits of detection and dissociation constants of both antibody pairs (48 with 155; B.1 with B.2) for the detection of CHIKV E1 and E2 were calculated by ELISA, dipstick, and/or lateral flow. The limits of detection were between 37.08 and 844.16 ng/mL (Table S1, Figure S2) which is within the range of E1 and E2 concentration found in acute chikungunya patients.

3.3. Performance of CHIKV E1/E2 ELISA

The E1/E2 CHIKV ELISA was validated using 100 PCR-confirmed chikungunya samples and 60 negative samples from Honduras. Sensitivity is defined as the fraction of true positive test results from the population of PCR-positive samples. Specificity is defined as the fraction of true negative test results from the samples that were PCR-negative for the tested serotype. The sensitivity and specificity of the developed E1/E2 ELISA were determined using various Cycle Threshold (Ct) value cutoffs (Table 1). Ct value cutoffs represent the number of PCR cycles at which generated fluorescence crosses a threshold. The OD₄₅₀ was inversely related to the Ct value, with a linear regression line of $y = -0.054x + 2.073$ and $p < 0.0002$ (Figure 1A). The overall sensitivity and specificity was 51% and 96.67%, respectively. Across the Ct range of 20 to 35, the performance of the ELISA ranged from 41.33% to 95.45% in sensitivity and 84.76%- 98.02% in specificity, with an area under the ROC curve (AUC) range of 0.61 to 0.94 (Table 1, Figure 2). A Ct value cutoff of 22 maximized the performance of the ELISA, which has a sensitivity of 95.45% and specificity of 92.03%. The optimal ELISA OD₄₅₀ cutoff value, in which the sum of the sensitivity and specificity was maximized, was 0.22 across all Ct values. Based on the performance analysis across Ct values, the CHIKV E1/E2 ELISA demonstrated high sensitivity and specificity particularly for low Ct cutoff values.




Figure 1. CHIKV E1/E2 ELISA and Lateral Flow Test compared to qPCR. The OD 450 or signal intensity of samples tested through ELISA (A) and lateral flow (B-D), respectively, are shown in relation to the PCR Ct values. The tests used either antibody Combination A (48 and 155) or Combination B (B.1 and B.2). The p values are <0.0002 (A), <0.0001 (B), <0.0002 (C), <0.0182 (D).




Figure 2. Performance of CHIKV E1/E2 ELISA Test. Receiver Operating Characteristic (ROC) Curve analysis of PCR- tested patient samples from Honduras. Incremental Ct values are used to characterize positive and negative samples, to which ELISA performance is compared. Test performance is demonstrated in terms of True Positive Rate (%) versus False Positive Rate (%).

Table 1. Performance of CHIKV E1/E2 ELISA Test. Area Under Curve (AUC) of ROC Curve, 95% Confidence Interval (95% CI), Optimal OD₄₅₀ cutoff, % sensitivity, % specificity, and sample counts were calculated for incremental PCR Ct cutoffs for the E1/E2 ELISA Test using antibody Combination A (48, 155).

CHIKV Combination A ELISA Receiver Operator Characteristic (ROC) Analysis (n = 160)																
Ct Cutoff	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35
AUC	0.86	0.91	0.94	0.92	0.89	0.86	0.83	0.81	0.79	0.77	0.72	0.71	0.70	0.65	0.61	0.61
95% CI	0.74 - 0.97	0.84 - 0.99	0.89 - 1.00	0.86 - - 0.98	0.80 - 0.97	0.77 - 0.95	0.74 - 0.93	0.72 - 0.91	0.70 - 0.88	0.68 - 0.86	0.63 - 0.82	0.62 - 0.81	0.61 - 0.79	0.55 - 0.74	0.52 - 0.71	0.52 - 0.70

OD ₄₅₀ Cutoff	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22	0.22
Sensitivity (%)	90.00	94.12	95.45	87.5	81.48	79.31	72.73	69.44	62.79	58.00	53.57	52.54	50.82	45.59	42.47	41.33
Specificity (%)	84.67	88.81	92.03	87.5	92.48	93.13	93.7	94.35	95.73	96.36	97.12	98.02	97.98	97.83	97.7	97.65
N Total Positive	150	143	138	136	133	131	127	124	117	110	104	101	99	92	87	85
N Total Negative	10	17	22	24	27	29	33	36	43	50	56	59	61	68	73	75

3.4. Performance of CHIKV E1/E2 Lateral Flow

Our lateral flow assay was used to detect CHIKV E1/E2 using either the mAbs 48 and 155 combination (Combination A), or mAbs B.1 and B.2 (Combination B). In total, 29 CHIKV samples were used from Honduras and Colombia to validate the lateral flow tests, of which the 19 samples from Honduras were used in both versions. The intensity of signal on the lateral flow was found to be inversely correlated with the Ct value (Figure 1B-D). The slopes of the linear regression line for Combination A in Honduras, Combination B in Honduras, and Combination B in Colombia were -0.07238, -0.05481, and -0.034, respectively. The p values were also <0.0001, <0.0002, <0.0182. When comparing the two antibody combinations in the lateral flow format side-by-side using the same Honduras samples, both versions perform optimally at a Ct cutoff of 27 with 100% sensitivity and 100% specificity (Figure 3A-3B, Table 2A-2B). At this Ct value, the optimal ELISA OD₄₅₀ cutoff was 0.57 and 0.53 for Combination A and Combination B, respectively. Across the Ct range of 20 to 29, the performance of Combination A ranged from 55.56% to 100% in sensitivity and 90.00% to 100% in specificity, with an AUC range of 0.78 to 1. The sensitivity and specificity of Combination B ranged from 55.56% to 100% and 83.33% to 100%, respectively, with an AUC range of 0.78 to 1 as well.

A total of ten samples from Colombia were used to validate the lateral flow test made from Combination B antibodies (Figure 3C, Table 2C). Data using Combination A antibodies was not collected. From this cohort, the sensitivity and specificity ranges were 85.71% to 100% and 77.78% to 100%, respectively. The optimal lateral flow intensity cutoff ranged from 0.614 to 0.6289 and the AUC range was 0.78 to 1. The test performed optimally at a Ct cutoff of 20 with 100% sensitivity and specificity. Across Honduras and Colombia, the Combination B test performed comparably with Combination A, demonstrating a high sensitivity and specificity over a range of Ct cutoff values.




Figure 3. Performance of CHIKV Lateral Flow Test. Receiver Operating Characteristic (ROC) Curve analysis of PCR-tested patient samples. The lateral flow test was constructed with Combination A antibodies using 19 samples from Honduras (A), Combination B antibodies using 19 samples from Honduras (B), and Combination B antibodies using 10 samples from Colombia (C). Incremental Ct values are used to characterize positive and negative samples, to which lateral flow test performance is compared. Test performance is demonstrated in terms of True Positive Rate (%) versus False Positive Rate (%).

Table 2. Performance of CHIKV E1/E2 Lateral Flow Test. Area Under Curve (AUC) of ROC Curve, 95% Confidence Interval (95% CI), Signal Intensity cutoff, % sensitivity, % specificity, and sample counts were calculated for incremental PCR Ct cutoffs for the E1/E2 lateral flow test using antibody Combination A (48 and 155) in Honduras (A) and antibody Combination B (B.1 and B.2) in Honduras (B) and Colombia (C).

A.

CHIKV Combination A Lateral Flow Receiver Operator Characteristic (ROC) Analysis - Honduras (n = 19)					
Ct Cutoff	20	21-24	25-26	27	28
AUC	0.96	0.95	0.94	1.00	0.81
95% CI	0.88 - 1.00	0.85 - 1.00	0.83 - 1.00	1.00 - 1.00	0.61 - 1.000
Lateral Flow Signal Intensity Cutoff	0.82	0.75	0.67	0.57	0.57
Sensitivity (%)	100	100	100	100	62.50
Specificity (%)	92.31	91.67	90.91	100	100
N Total Positive	13	12	11	9	3
N Total Negative	6	7	8	10	16

B

CHIKV Combination B Lateral Flow Receiver Operator Characteristic (ROC) Analysis - Honduras (n = 19)				
Ct Cutoff	20	21-26	27	28
AUC	0.94	0.93	1.00	0.81
95% CI	0.82 - 1.00	0.82 - 1.00	1.00 - 1.00	0.61 - 1.00
Lateral Flow Signal Intensity Cutoff	0.72	0.53	0.53	0.53
Sensitivity (%)	83.33	100	100	62.50
Specificity (%)	92.31	75.00	100	100
N Total Positive	13	12	9	3
N Total Negative	6	7	10	16

C

CHIKV Combination B Lateral Flow Receiver Operator Characteristic (ROC) Analysis - Colombia (n = 10)			
Ct Cutoff	18-19	20	21
AUC	0.86	1.00	0.78
95% CI	0.60 - 1.00	1.00 - 1.00	0.51 - 1.00
Lateral Flow Signal Intensity Cutoff	0.63	0.59	0.56
Sensitivity (%)	100	100	77.78
Specificity (%)	85.71	100	100

N Total Positive	7	4	1
N Total Negative	3	6	9

4. Discussion

In this study we present two assays - an antigen-based ELISA and lateral flow test - which are alternatives to relying on RT-PCR methods or serology for the timely detection or diagnosis of CHIKV infections. The rate of CHIKV infections has markedly increased within the past two decades, yet clinical diagnostic methods remain impractical for public health response. Presently, there are no commercially available methods for early high-throughput screening or rapid tests for CHIKV. Diagnosis by PCR is common and can be used to diagnose early stages of fever, yet remains costly in terms of time, labor, and resources. PCR also requires experienced personnel for sample preparation and nucleic acid extraction. This method is also prone to error due to the degradation of RNA and the potential for amplicon contamination between samples. Serological methods, such as an IgG/IgM-based ELISAs, are also common yet are limited to post-acute phase diagnosis [25–29]. Studies show that these tests perform extremely poorly during the first week of fever, as IgM levels are detectable only between day 4 and 7 after illness onset [1]. IgM assays also remain impractical for early detection as these antibodies can exist in the body months after illness [28].

There currently exist few reports of antigen-based assays for CHIKV. Shukla et al. developed an antigen-capture ELISA by producing hyperimmune sera from mice and rabbits and using the antibodies in a sandwich ELISA format [28]. Although the test was in 96% concordance with RT-PCR, the samples were collected from CHIKV patients in India, thus limiting the performance of the test to the detection of the CHIKV Asian lineage [30]. An immunochromatographic assay was reported by Okabayashi et al. (2015) in which monoclonal antibodies against the E1 protein were developed and used to detect CHIKV antigen [31–33]. However, this test targets only one envelope protein and displays a limit of detection of 1×10^5 PFU/mL.

Our study introduces an antigen ELISA and lateral flow tests with high sensitivity and specificity for the detection of both CHIKV E1 and E2 - addressing the dearth of antigen-based tests and the several limitations present in previously reported assays. We performed an extensive antibody screening to maximize the performance of antigen capture, as well as high sensitivity and specificity in two different assay formats across a range of PCR Ct cutoff values, highlighting the potential for the broad application of these assays. Moreover, our assays are tested with samples from Latin America which has previously been underrepresented in the validation of the previous antigen-based tests. Latin American countries, particularly Honduras and Colombia, bear a sizable burden of dengue, Zika, and chikungunya infections - three mosquito-borne diseases which share several nonspecific symptoms, often leading to misdiagnosis and uncertainty. After the introduction of chikungunya to the Caribbean in 2013, the disease has rapidly spread in the Americas, with 998,015 cases reported in 2016 alone [34,35]. Our CHIKV antigen-based assays development and validation are significant because they display high sensitivity and specificity in samples from Latin America. The lateral flow tests reached maximum sensitivity and specificity over a Ct value range of 20-27 and 21-27 for Colombia and Honduras, respectively. Our lateral flow tests reached 100% sensitivity and specificity using either of the two antibody pairs selected from screening. The ELISA format reached sensitivity and specificity reaching 95.45% and 98.02%, respectively, with a Ct cutoff of 22. However, the accuracy significantly decreases as the Ct values rise for all three assays.

The main significance of these antigen-based CHIKV diagnostic assays is the ability to detect virus within the first 5 days of fever onset. Sensitivity was likely affected by samples with low viremia, possibly because sample collection took place in the latter end of the optimal diagnostic window or some individuals had lower viremia than others. Samples with a Ct value close to 35, for instance, are more difficult to detect than samples with a low Ct value due to the lower viremia. As shown by the linear regression models of assays signals in relation to the Ct values, the signal decreases with increasing Ct values. Thus, the assays perform more accurately with samples with more virus and lower Ct values. Moreover, in Honduras, temporary temperature fluctuations of

stored samples possibly led to protein degradation, affecting sensitivity values. Nevertheless, the AUC remained close to 1 for all countries including Honduras, for both the lateral flows and ELISA. Future validation tests will aim to include patient samples from Asia and Africa to expand validation of the tests with different CHIKV lineages.

The dual opportunities presented by highly specific and sensitive antigen-based lateral flow tests and ELISAs for CHIKV diagnosis are significant. The lateral flow test offers an extremely low-cost and rapid method for early detection in both low and abundant resource settings. The ELISA offers a method for high-throughput screening that is more accessible than PCR. Particularly during outbreaks, both assays may enable systems of hospital triage and disease surveillance that better equip public health response. When the disease is detected within the first five days of fever, early, supportive treatment may be administered to prevent progression to severe forms of CHIKV such as neurological disorders, durable joint pain, and death. Moreover, an early diagnosis enables more targeted care, avoiding the large costs that hospitals incur from a late diagnosis or misdiagnosis. Early detection of infection can also provide critical data to prevent further transmission and alarm surveillance systems.

Ideally, these antigen-based tests may be used in conjunction with serology-based tests, particularly when days of patient fever are uncertain or lie between diagnostic windows. Taken together, this study describes the development and validation of a highly specific and sensitive CHIKV E1/E2 rapid lateral flow and ELISA assay. These antigen-based assays are a crucial component to enabling early detection of disease for proper and timely care, economic allocation of clinical resources, and adequate epidemiological measures.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Binding of CHIKV antibodies, Figure S2: Limit of Detection of Antibody Pairs to detect CHIKV, Table S1: Limits of Detection of Antibody Pairs to detect CHIKV

Author Contributions:

Conceptualization, I.B.;

methodology, A.R., I.B., N.S., C.N., D.M.C.

software, A.R., H.P.;

validation, A.R., I.B., and H.P., I.L., M.M., L.A.V.

formal analysis, A.R., I.B., N.S., B.B.H., H.P., C.N., D.M.C., I.L., L.P., K.G., M.M., A.M.R.T., L.A.V., M.G., N.A.G.R., M.D., L.G.;

investigation, A.R., I.B., B.B.H., N.S., H.P., C.N., D.M.C., I.L., K.G., L.P., M.H., D.G., M.D., L.G.;

resources, I.B., I.L., M.M., L.A.V., M.D., L.G.

data curation, A.R., I.B., N.S., B.B.H., H.P., C.N., D.M.C., I.L., L.P., K.G., M.M., A.M.R.T., L.A.V., M.G., N.A.G.R., M.H., D.G., M.D., L.G.;

writing—original draft preparation, A.R., I.B.

writing—review and editing, A.R., I.B., N.S., B.B.H., H.P., C.N., D.M.C., I.L., L.P., K.G., M.M., A.M.R.T., L.A.V., M.G., N.A.G.R., M.H., D.G., M.D., L.G.;

visualization, A.R., H.P.;

supervision, I.B., L.G.

project administration, I.B., L.G.

funding acquisition, I.B., L.G.

Funding: This work was funded in part by an award (AI100190) from the U.S. Public Health Service. L.V., M.R., and N.A.G.R. received support from the Science, Technology and Innovation Fund, Colombia–Fondo de Ciencia, Tecnología e Innovación of Sistema General de Regalías (BPIN 2013000100011) and the AEDES Network. We acknowledge support from the Tata Foundation.

Acknowledgments: We would like to thank Jorge Muñoz-Jordán and Freddy Medina for their project guidance and Arnold Salcedo for his help with ELISA protocols.

Conflicts of Interest: A.R., I.B., B.B.H., N.S., & L.G. are affiliated or employed by E25Bio Inc. (www.e25bio.com), a company that develops point-of-care diagnostics for fever-causing infectious agents. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Pialoux G: Gaüzère B-A, Jauréguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. *Lancet Infect Dis.* 2007 May;7(5):319–27.
2. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. *Viruses* [Internet]. 2017 Dec 1 [cited 2020 Jan 14];9(12). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744143/>
3. Vairo F, Haider N, Kock R, Ntoumi F, Ippolito G, Zumla A. Chikungunya: Epidemiology, Pathogenesis, Clinical Features, Management, and Prevention. *Infect Dis Clin North Am.* 2019;33(4):1003–25.
4. Sengupta S, Mukherjee S, Haldar SK, Bhattacharya N, Tripathi A. Re-emergence of Chikungunya virus infection in Eastern India. *Braz J Microbiol* [Internet]. 2020 Jan 2 [cited 2020 Jan 14]; Available from: <https://doi.org/10.1007/s42770-019-00212-0>
5. Rueda JC, Santos AM, Angarita J-I, Giraldo RB, Saldarriaga E-L, Ballesteros Muñoz JG, et al. Demographic and clinical characteristics of chikungunya patients from six Colombian cities, 2014–2015. *Emerg Microbes Infect.* 2019;8(1):1490–500.
6. Silva MMO, Tauro LB, Kikuti M, Anjos RO, Santos VC, Gonçalves TSF, et al. Concomitant Transmission of Dengue, Chikungunya, and Zika Viruses in Brazil: Clinical and Epidemiological Findings From Surveillance for Acute Febrile Illness. *Clin Infect Dis.* 2019 Sep 27;69(8):1353–9.
7. Waggoner JJ, Gresh L, Vargas MJ, Ballesteros G, Tellez Y, Soda KJ, et al. Viremia and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus. *Clin Infect Dis.* 2016 Dec 15;63(12):1584–90.
8. Proesmans S, Katshongo F, Milambu J, Fungula B, Mavoko HM, Ahuka-Mundeke S, et al. Dengue and chikungunya among outpatients with acute undifferentiated fever in Kinshasa, Democratic Republic of Congo: A cross-sectional study. *PLOS Neglected Tropical Diseases.* 2019 Sep 5;13(9):e0007047.
9. Carvalho FR, Medeiros T, Vianna RA de O, Douglass-James G, Nunes PCG, Quintans MDS, et al. Simultaneous circulation of arboviruses and other congenital infections in pregnant women in Rio de Janeiro, Brazil. *Acta Trop.* 2019 Apr;192:49–54.
10. Bagno FF, Figueiredo MM, Villarreal J, Pereira G de C, Godoi LC, da Fonseca FG. Undetected Chikungunya virus co-infections in a Brazilian region presenting hyper-endemic circulation of Dengue and Zika. *J Clin Virol.* 2019 Apr;113:27–30.
11. Mardekian SK, Roberts AL. Diagnostic Options and Challenges for Dengue and Chikungunya Viruses [Internet]. *BioMed Research International.* 2015 [cited 2020 Feb 18]. Available from: <https://www.hindawi.com/journals/bmri/2015/834371/>
12. Petitdemange C, Wauquier N, Vieillard V. Control of immunopathology during chikungunya virus infection. *Journal of Allergy and Clinical Immunology.* 2015 Apr 1;135(4):846–55.
13. Ng L-C, Tan L-K, Tan C-H, Tan SSY, Hapuarachchi HC, Pok K-Y, et al. Entomologic and Virologic Investigation of Chikungunya, Singapore. *Emerg Infect Dis.* 2009 Aug;15(8):1243–9.
14. Carletti F, Bordi L, Chiappini R, Ippolito G, Sciarrone MR, Capobianchi MR, et al. Rapid detection and quantification of Chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay. *Am J Trop Med Hyg.* 2007 Sep;77(3):521–4.
15. Hasebe F, Parquet MC, Pandey BD, Mathenge EGM, Morita K, Balasubramaniam V, et al. Combined detection and genotyping of Chikungunya virus by a specific reverse transcription-polymerase chain reaction. *J Med Virol.* 2002 Jul;67(3):370–4.
16. Joseph AY, Babu VS, Dev SS, Gopalakrishnapai J, Harish M, Rajesh MD, et al. Rapid detection and characterization of Chikungunya virus by RT-PCR in febrile patients from Kerala, India. *Indian journal of experimental biology.* 2008 Aug;46(8):573–8.

17. Laurent P, Le Roux K, Grivard P, Bertil G, Naze F, Picard M, et al. Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus. *Clin Chem*. 2007 Aug;53(8):1408–14.
18. Panning M, Charrel RN, Mantke OD, Landt O, Niedrig M, Drosten C. Coordinated Implementation of Chikungunya Virus Reverse Transcription–PCR. *Emerg Infect Dis*. 2009 Mar;15(3):469–71.
19. Yap G, Pok K-Y, Lai Y-L, Hapuarachchi H-C, Chow A, Leo Y-S, et al. Evaluation of Chikungunya Diagnostic Assays: Differences in Sensitivity of Serology Assays in Two Independent Outbreaks. *PLOS Neglected Tropical Diseases*. 2010 Jul 20;4(7):e753.
20. Nguyen HC, Park H, Shin H-J, Nguyen NM, Nguyen ATV, Trinh T-TT, et al. Fluorescent Immunosorbent Assay for Chikungunya Virus Detection. *INT*. 2019;62(3):145–55.
21. Bagno FF, Godoi LC, Salazar N, Pereira G de C, Figueiredo MM, Fonseca FG da. Development of an enzyme-linked immunosorbent assay using recombinant protein antigen for the diagnosis of Chikungunya virus. *Data in Brief*. 2019 Aug 1;25:104015.
22. Kikuti M, Tauro LB, Moreira PSS, Nascimento LCJ, Portilho MM, Soares GC, et al. Evaluation of two commercially available chikungunya virus IgM enzyme-linked immunoassays (ELISA) in a setting of concomitant transmission of chikungunya, dengue and Zika viruses. *Int J Infect Dis*. 2019 Nov 6;91:38–43.
23. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. *PLoS Pathog*. 2013;9(4):e1003312.
24. Bosch I, de Puig H, Hiley M, Carré-Camps M, Perdomo-Celis F, Narváez CF, et al. Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. *Sci Transl Med*. 2017 Sep 27;9(409).
25. Blacksell SD, Tanganuchitcharnchai A, Jarman RG, Gibbons RV, Paris DH, Bailey MS, et al. Poor Diagnostic Accuracy of Commercial Antibody-Based Assays for the Diagnosis of Acute Chikungunya Infection ▽. *Clin Vaccine Immunol*. 2011 Oct;18(10):1773–5.
26. Rianthavorn P, Wuttirattanakowit N, Prianantathavorn K, Limpaphayom N, Theamboonlers A, Poovorawan Y. Evaluation of a rapid assay for detection of IgM antibodies to chikungunya. *Southeast Asian J Trop Med Public Health*. 2010 Jan;41(1):92–6.
27. Chopra A, Anuradha V, Lagoo-Joshi V, Kunjir V, Salvi S, Saluja M. Chikungunya virus aches and pains: an emerging challenge. *Arthritis Rheum*. 2008 Sep;58(9):2921–2.
28. Hoarau J-J, Jaffar Bandjee M-C, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. *J Immunol*. 2010 May 15;184(10):5914–27.
29. Grivard P, Le Roux K, Laurent P, Fianu A, Perrau J, Gigan J, et al. Molecular and serological diagnosis of Chikungunya virus infection. *Pathol Biol*. 2007 Dec;55(10):490–4.
30. Shukla J, Khan M, Tiwari M, Sannarangaiah S, Sharma S, Rao PVL, et al. Development and evaluation of antigen capture ELISA for early clinical diagnosis of chikungunya. *Diagn Microbiol Infect Dis*. 2009 Oct;65(2):142–9.
31. Okabayashi T, Sasaki T, Masrinoul P, Chantawat N, Yoksan S, Nitatpattana N, et al. Detection of chikungunya virus antigen by a novel rapid immunochromatographic test. *J Clin Microbiol*. 2015 Feb;53(2):382–8.
32. Jain J, Okabayashi T, Kaur N, Nakayama E, Shioda T, Gaiind R, et al. Evaluation of an immunochromatography rapid diagnosis kit for detection of chikungunya virus antigen in India, a dengue-endemic country. *Virology Journal*. 2018 May 11;15(1):84.
33. Huits R, Okabayashi T, Cnops L, Barbé B, Van Den Berg R, Bartholomeeusen K, et al. Diagnostic accuracy of a rapid E1-antigen test for chikungunya virus infection in a reference setting. *Clin Microbiol Infect*. 2018 Jan;24(1):78–81.
34. Fernández-Salas I, Danis-Lozano R, Casas-Martínez M, Ulloa A, Bond JG, Marina CF, et al. Historical inability to control *Aedes aegypti* as a main contributor of fast dispersal of chikungunya outbreaks in Latin America. *Antiviral Res*. 2015 Dec;124:30–42.
35. World Health Organization. World Health Organization [Internet]. 2019 [cited 2019 Apr 17]. Available from: <https://www.who.int>